drugset / Trial / NCT01969721

Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients

NCT01969721

Phase 3 Completed 229 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

The objective of the trial is to compare the lung function profile of once daily treatment with tiotropium+olodaterol FDC \[2.5/ 5µg and 5/ 5µg\] delivered by the RESPIMAT with the lung function profile of twice daily treatment with fluticasone propionate+salmeterol FDC \[250/50µg and 500/50µg\] delivered by the Accuhaler® after 6 weeks of treatment.

Timeline

Start
2013-10
Primary completion
2015-01
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluticasone propionate Other / unclassified 250 ug Inhaled
Comparator Fluticasone propionate Other / unclassified 500 ug Inhaled
Subject Olodaterol Small molecule 5 ug Inhaled
Comparator Salmeterol Other / unclassified 50 ug Inhaled
Subject Tiotropium Other / unclassified 2.5 ug Inhaled
Subject Tiotropium Other / unclassified 5 ug Inhaled